The Effect of Carthamus tinctorius in Combination with Dexamethasone on Coagulation Markers in Mice Induced by SARS-CoV2 Spike Protein

Document Type : Original paper

Authors

1 Master Program in Biomedical Sciences. Faculty of Medicine Universitas Indonesia.

2 Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.

3 Department of Microbiology, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.

4 Doctoral Program in Biomedical Sciences, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.

5 Faculty of Medicine, Universitas Muhammadiyah Makassar, South Sulawesi, Indonesia.

6 Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.

Abstract

Background and objectives: COVID-19 is a respiratory condition frequently followed by an inflammatory reaction in addition to respiratory symptoms, which disrupts the blood coagulation process. One drug candidate known to have dual anti-inflammatory and anticoagulating effects is hydroxysafflor yellow A, an active compound found in the flowers of Carthamus tinctorius. Therefore, this study analysed the effect of C. tinctorius ethanol extract in combination with dexamethasone on coagulation biomarkers in mice induced with the SARS-CoV2 spike protein. Method: Flowers of Carthamus tinctorius were extracted with 98% ethanol. The concentrated extract was used in the study. Twenty-five Balb/c mice, comprising five healthy controls and twenty mice were induced with SARS-CoV2. The SARS-CoV2-induced mice were then randomized to receive seven days of treatment, which consisted of vehicle or dexamethasone 2.5 mg/kg BW, dexamethasone 2.5 mg/kg BW + C. tinctorius extract 400 mg/kg BW, or dexamethasone 2.5 mg/kg BW + C. tinctorius extract 800 mg/kg BW. Subsequently, the lungs and blood of the mice were analysed. Results: SARS-CoV2-induced mice increased all the coagulation markers studied. Treatment with dexamethasone alone or in combination with C. tinctorius extract 400 mg/kg BW did not cause reductions in D-dimer, plasminogen activator inhibitor-1, lactate dehydrogenase, platelet-to-leucocyte ratio, or neutrophil-to-leucocyte ratio. However, dexamethasone co-treatment with C. tinctorius extract at 800 mg/kg BW resulted in the normalization of D-dimer, PAI-1, and NLR in SARS-CoV2-induced mice. Conclusion: The administration of high dose of C. tinctorius flower extracts (800 mg/kg BW) in combination with dexamethasone showed the benefit of minimizing the coagulation disorder in SARS-CoV2.

Keywords

Main Subjects

References

  • Naseer S, Khalid S, Parveen S, Abbass K, Song H, Achim MV. COVID-19 outbreak: impact on global economy. Front Public Health. 2022; 10: 1–13.
  • Visuddho V, Subagjo A, Setyoningrum RA, Rosyid AN. Survival analysis and outcome prediction of COVID-19 patients: a retrospective observational study from tertiary referral hospital in Indonesia. Trop Biomed. 2022; 39(2): 239–246.
  • Shi S, Liu X, Xiao J, Wang H, Chen L, Li J, Han K. Prediction of adverse clinical outcomes in patients with coronavirus disease 2019. J Clin Lab Anal. 2021; 35(1): 1–9.
  • Goswami J, MacArthur TA, Sridharan M, Pruthi RK, McBane RD, Witzig TE, Park MS. A review of pathophysiology, clinical features, and management options of COVID-19 associated coagulopathy. Shock. 2021; 55(6): 700–716.
  • Berkman SA, Tapson VF. COVID-19 and its implications for thrombosis and anticoagulation. Semin Respir Crit Care Med. 2021; 42(2): 316–326.
  • Hanff TC, Mohareb AM, Giri J, Cohen JB, Chirinos JA. Thrombosis in COVID-19. Am J Hematol. 2020; 95(12): 1578–1589.
  • Meisinger C, Kirchberger I, Warm TD, Hyhlik-Dürr A, Goßlau Y, Linseisen J. Elevated plasma D-Dimer concentrations in adults after an outpatient-treated COVID-19 infection. Viruses. 2022; 14(11): 2441–2451.
  • Ekholm M, Kahan T. The impact of the renin-angiotensin-aldosterone system on inflammation, coagulation, and atherothrombotic complications, and to aggravated COVID-19. Front Pharmacol. 2021; 12: 1–20.
  • World Health Organization. Therapeutics and COVID-19 living guideline. Geneva: World Health Organization, 2023.
  • Tang Y, Liu J, Zhang D, Xu Z, Ji J, Wen C. Cytokine storm in COVID-19: the current evidence and treatment strategies. Front Immunol. 2020; 11: 1–13.
  • Group RC, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi E, Prudon B, Green C, Felton T, Chadwick D, Rege K, Fegan C, Chappell LC, Faust SN, Jaki T, Jeffery K, Montgomery A, Rowan K, Jusczal E, Baillie JK, Haynes R, Landray MJ. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021; 384(8): 693–704.
  • Ghalilah K, Sabir AM, Alvi IA, Alharbi M, Basabrain A, Aljundi M, Almohammadi G, Almuairfi Z, Alharbi R, Ahmed AAE. Effects of anticoagulants and corticosteroids therapy in patients affected by severe COVID-19 pneumonia. J Pharm Res Int. 2021; 33(43): 460–479.
  • Hassan AT, Elmoniem AEA, Abdelrady MM, Mohamed ME, Mokhtar MA, Elsherif AA, Saied GM, Kasem SM. Challenges in steroid and anticoagulant therapy in severe COVID-19 pneumonia: a prospective study. Antibiotics. 2021; 10(10): 1214–1228.
  • Hara H, Uemura Y, Hayakawa K, Togano T, Asai Y, Matsunaga N, Terada M, Ohtsu K, Shimizu Y, Sato L, Ishikane M, Kinoshita-Iwamoto N, Shibata T, Kondo M, Izumi K, Sugiura W, Ohmagari N. Evaluation of the efficacy of anticoagulation therapy in reducing mortality in a nationwide cohort of hospitalized patients with coronavirus disease in Japan. Int J Infect Dis. 2021; 112(9): 111–116.
  • Zhao F, Wang P, Jiao Y, Zhang X, Chen D, Xu H. Hydroxysafflor yellow a: a systematical review on botanical resources, physicochemical properties, drug delivery system, pharmacokinetics, and pharmacological effects. Front Pharmacol. 2020; 11: 1–21.
  • Zafari M, Ebadi A, Jahanbakhsh S, Sedghi M. Safflower (Carthamus tinctorius) biochemical properties, yield, and oil content affected by 24-epibrassinosteroid and genotype under drought stress. J Agric Food Chem. 2020; 68(22): 6040–6047.
  • Delshad E, Yousefi M, Sasannezhad P, Rakhshandeh H, Ayati Z. Medical uses of Carthamus tinctorius (Safflower): a comprehensive review from traditional medicine to modern medicine. Electron Physician. 2018; 10(4): 6672–6681.
  • Liao Y, Liang F, Liu H, Zheng Y, Li P, Peng W, Su W. Safflower yellow extract inhibits thrombus formation in mouse brain arteriole and exerts protective effects against hemorheology disorders in a rat model of blood stasis syndrome. Biotechnol Biotechnolo Equip. 2018; 32(2): 487–497.
  • Zhang LL, Tian K, Tang ZH, Chen XJ, Bian ZX, Wang YT, Lu JJ. Phytochemistry and pharmacology of Carthamus tinctorius Am J Chin Med. 2016; 44(2): 197–226.
  • Wang XT, Peng Z, An YY, Shang T, Xiao G, He S, Chen X, Zhang H, Wang Y, Wang T, Zhang HJ, Gao X, Zhu Y, Feng Y. Paeoniflorin and hydroxysafflor yellow a in xuebijing injection attenuate sepsis-induced cardiac dysfunction and inhibit proinflammatory cytokine production. Front Pharmacol. 2020; 11: 1–19.
  • Li HX, Han SY, Wang XW, Ma X, Zhang K, Wang L, Ma ZZ, Tu PF. Effect of the carthamins yellow from Carthamus tinctorius on hemorheological disorders of blood stasis in rats. Food Chem Toxicol. 2009; 47(8): 1797–1802.
  • Ding T, Jian L, Zhao J, Liu S, Zhang J, Wu SH. Ethanol extract of Carthamus tinctorius shows anti-thrombosis activity in rats. Afr J Tradit Complement Altern Med. 2015; 12(3): 120–124.
  • Hansur L, Louisa M, Wuyung PE. Approach for the study of COVID-19 infection and vaccine development using mice model: a narrative review. AIP Conf Proc. 2022; 2537(1): 1–7.
  • Bai Y, Lu P, Han C, Yu C, Chen M, He F, Yi D, Wu L. Hydroxysafflor yellow A (HSYA) from flowers of Carthamus tinctorius and its vasodilatation effects on pulmonary artery. Molecules. 2012; 17(12): 14918–14927.
  • Ghorbani E, Kelestheri RH, Shahbazi M, Moradi F, Sadri M. Optimization of extraction yield of carthamine and safflower yellow pigments from safflower (Carthamus tinctorius) under different treatments and solvent systems. Res J Pharmacogn. 2015; 2(1): 17–23.
  • Zong X, Li L, Zhang H, Li B, Liu C. Preparative separation of hydroxyl safflower yellow A and anhydrosafflor yellow B in plant extract of Carthamus tinctorius by reverse-phase medium-pressure liquid chromatography. J Liq Chromatogr Relat Technol. 2013; 36(14): 1947–1958.
  • Zang BX, Jin M, Si N, Zhang Y, Wu W, Piao YZ. Antagonistic effect of hydroxysafflor yellow A on the platelet activating factor receptor. Yao Xue Xue Bao. 2002; 37(9): 696–699.
  • Sun Y, Xu DP, Qin Z, Wang PY, Hu BH, Yu JG, Zhao Y, Cai B, Chen YL, Lu M, Liu JG, Liu X. Protective cerebrovascular effects of hydroxysafflor yellow A (HSYA) on ischemic stroke. Eur J Pharmacol. 2018; 818(1): 604–609.
  • Baltan E, Serin E, Avci BY, Akilli IK, Çinar AS. The relationship between plasminogen activator inhibitor-1 levels and the course of disease in COVID-19 patients. Turk J Biochem. 2022; 47(5): 672–679.
  • Zhao R, Su Z, Komissarov AA, Liu SL, Yi G, Idell S, Matthay MA, Ji HL. Associations of D-Dimer on admission and clinical features of COVID-19 patients: a systematic review, meta-analysis, and meta-regression. Front Immunol. 2021; 12: 1–12.
  • Esmaeel HM, Ahmed HA, Elbadry MI, Khalaf AR, Mohammed NA, Mahmoud HA, Taha EM. Coagulation parameters abnormalities and their relation to clinical outcomes in hospitalized and severe COVID-19 patients: prospective study. Sci Rep. 2022; 12(1): 13155–13163.
  • Thachil J, Agarwal S. Understanding the COVID-19 coagulopathy spectrum. Anaesthesia. 2020; 75(11): 1432–1436.
  • Corey KM, Olson LB, Naqvi IA, Morrison SA, Davis C, Nimjee SM, Que LG, Bachelder RE, Kraft BD, Chen L, Nair SK, Levy JH, Sullenger BA. Suppression of fibrinolysis and hypercoagulability, severity of hypoxemia, and mortality in COVID-19 patients: a retrospective cohort study. Anesthesiology. 2022; 137(1): 67–78.
  • Henry BM, Aggarwal G, Wong J, Benoit S, Vikse J, Plebani M, Lippi G. Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: a pooled analysis. Am J Emerg Med. 2020; 38(9): 1722–1726.
  • Vidal-Cevallos P, Higuera-De-La-Tijera F, Chávez-Tapia NC, Sanchez-Giron F, Cerda-Reyes E, Rosales-Salyano VH, Servin-Caamano A, Vazquez-Medina M, Mendez-Sanchez N. Lactate-dehydrogenase associated with mortality in hospitalized patients with COVID-19 in Mexico: a multi-centre retrospective cohort study. Ann Hepatol. 2021; 24: 100338–100343.
  • Callejas Rubio JL, Aomar Millan I, Moreno-Higueras M, Martín Ripoll L, Yuste Osorio E, Ríos-Fernández R. Caution with the use of dexamethasone in patients with COVID-19 in its initial phases. Rev Clin Esp (Barc). 2021; 221(10): 592–595.
  • Yang X, Yang Q, Wang Y, Wu Y, Xu J, Yu Y, Shang Y. Thrombocytopenia and its association with mortality in patients with COVID-19. J Thromb Haemost. 2020; 18(6): 1469–1472.
  • Machlus KR, Cardenas JC, Church FC, Wolberg AS. Causal relationship between hyperfibrinogenemia, thrombosis, and resistance to thrombolysis in mice. Blood. 2011; 117(18): 4953–4963.
  • Dolhnikoff M, Duarte-Neto AN, de Almeida Monteiro RA, da Silva LFF, de Oliveira EP, Saldiva PHN, Mauad T, Negri EM. Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19. J Thromb Haemost. 2020; 18(6): 1517–1519.
  • Gattinoni L, Chiumello D, Caironi P, Busana M, Romitti F, Brazzi L. COVID-19 pneumonia: different respiratory treatments for different phenotypes? Intensive Care Med. 2020; 46(6): 1099–1102.
  • Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, Psaltopoulou T, Gerotziafas G, Dimopoulos M. Hematological findings and complications of COVID-19. Am J Hematol. 2020; 95(7): 834–847.
  • Rajendran K, Krishnasamy N, Rangarajan J, Rathinam J, Natarajan M, Ramachandran A. Convalescent plasma transfusion for the treatment of COVID-19: systematic review. J Med Virol. 2020; 92(9): 1475–1483.
  • Zhu X, Song H, Chen Y, Han F, Wang Q, Cui Y. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in blood to distinguish lung cancer patients from healthy subjects. Dis Markers. 2020; Article ID 8844698.
  • Dymicka-Piekarska V, Dorf J, Milewska A, Łukaszyk M, Kosidło JW, Kamińska J, Wolszczak-Biedrzycka B, Naumnik W. Neutrophil/lymphocyte ratio (NLR) and lymphocyte/monocyte ratio (LMR) - risk of death inflammatory biomarkers in patients with COVID-19. J Inflamm Res. 2023; 16: 2209–2222.
  • Kosidło JW, Wolszczak-Biedrzycka B, Matowicka-Karna J, Dymicka-Piekarska V, Dorf J. Clinical significance and diagnostic utility of NLR, LMR, PLR and SII in the course of COVID-19: a literature review. J Inflamm Res. 2023; 16(1): 539–562.
  • Sarkar S, Kannan S, Khanna P, Singh AK. Role of platelet-to-lymphocyte count ratio (PLR), as a prognostic indicator in COVID-19: a systematic review and meta-analysis. J Med Virol. 2022; 94(1): 211–221.
  • Hafkamp FMJ, Mol S, Waqué I, De Jong EC. Dexamethasone, but not vitamin D or A, dampens the inflammatory neutrophil response to protect at-risk COVID-19 patients. Immune Netw. 2022; 22(4): 36–48.
  • Moisa E, Corneci D, Negoita S, Filimon CR, Serbu A, Negutu MI, Grintescu IM. Dynamic changes of the neutrophil-to-lymphocyte ratio, systemic inflammation index, and derived neutrophil-to-lymphocyte ratio independently predict invasive mechanical ventilation need and death in critically Ill COVID-19 patients. Biomedicines. 2021; 9(11): 1656–1667.
  • Yao R, Cao Y, Jiang R, Zhang X, Li F, Wang S. Pharmacokinetic characteristics of hydroxysafflor yellow A in normal and diabetic cardiomyopathy mice. Biomed Chromatogr. 2021; 35(10): 5173–5203.
  • Chu D, Liu W, Huang Z, Liu S, Fu X, Liu K. Pharmacokinetics and excretion of hydroxysafflor yellow A, a potent neuroprotective agent from safflower, in rats and dogs. Planta Med. 2006; 72(5): 418–423.
  • Lee HB, Blaufox MD. Blood volume in the rat. J Nucl Med. 1985; 26(1): 72–76.
  • Adamska I, Biernacka P. Bioactive substances in safflower flowers and their applicability in medicine and health-promoting foods. Int J Food Sci. 2021; Article ID 6657639.
Research Journal of Pharmacognosy
Volume 10, Issue 4
October 2023
Pages 31-41

Files

Share

How to cite

Statistics